Natera Inc (NTRA) stock price

Natera Inc (NTRA) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $361.62 (-1.28%), Market cap $29.23B, 52-week low–high $133.66 ~ $254.40.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-g

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Natera Inc are updated in real time on BlackAll Trade.

Natera Inc financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current Natera Inc (NTRA) stock price?

Natera Inc trades at $361.62 (-1.28%). Real-time quotes and charts are available on BlackAll Trade.

What is the Natera Inc (NTRA) market cap?

Natera Inc has a market cap of about $29.23B.

What does Natera Inc (NTRA) do?

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment,